Cell Therapies in Oncology: Clinical Pipeline Analysis & Development Trends | G7 and China | 2021

Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly expanding and claims the largest number of immuno-oncology therapies in clinical development. Chimeric antigen receptor (CAR) T-cell therapies lead the way; six treatments are already approved for hematological malignancies. Although CAR T cells dominate the pipeline, other cell therapies are beginning to gain traction, including tumor-infiltrating lymphocyte (TIL) therapies, T-cell receptor (TCR) therapies, and natural killer (NK) cell therapies. This Special Topics report provides a comprehensive view of the current cell therapy landscape and pipeline, with coverage of therapies in early-phase through late-phase development in a range of oncology indications.

QUESTIONS ANSWERED

• What is the current landscape for approved CAR T-cell therapies? What are the key trends? What impact will these treatments have on their respective oncology indications?
• What does the cell therapy pipeline look like by phase of development? What are the key classes of therapies? Who are the key developers? In which geographies is development focused?
• What are the key trends in the development of cell therapies? In which oncology indications are cell therapies being investigated? What are the key targets in solid and hematological tumors?

CONTENT HIGHLIGHTS

Geographies: United States, EU5, Japan, and China.

Primary and secondary market research: In-depth interviews with six key opinion leaders (hematologist-oncologists and medical-oncologists); analysis of industry and company reports; peer-reviewed journals; pipeline databases; industry / scientific conferences; news; media

Therapies covered:

• Current therapies: CAR T-cell therapies (e.g., Yescarta, Kymriah, Tecartus, Breyanzi, Abecma, Carteyva) and dendritic-cell therapies (e.g., Provenge)
• Emerging therapies: Therapies in Phase III development, including CAR T-cell therapies, TIL therapies, TCR therapies, NK-cell therapies; coverage of select early-phase cell therapies

PRODUCT DESCRIPTION

Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive pipeline analysis of the cell therapy landscape in relevant oncology indications.